Faeth goes public in merger with Sensei, nets $200M in stock salenews2026-02-18T13:00:57+00:00February 18th, 2026|Endpoints News|
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfrontnews2026-02-18T11:31:31+00:00February 18th, 2026|Endpoints News|
Gilead gets cancer drug from China-based Genhouse for $80M upfrontnews2026-02-13T18:53:40+00:00February 13th, 2026|Endpoints News|
Madrigal pads MASH pipeline with six siRNAs from China’s Ribonews2026-02-11T15:49:41+00:00February 11th, 2026|Endpoints News|
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisitionnews2026-02-09T15:25:12+00:00February 9th, 2026|Endpoints News|
Lilly returns to Innovent to partner on cancer and immune diseasesnews2026-02-09T09:28:38+00:00February 9th, 2026|Endpoints News|
Hims adds Grail’s cancer test amid questions about widespread usenews2026-02-04T14:00:32+00:00February 4th, 2026|Endpoints News|
GSK returns rights to Wave’s RNA editing program for AATDnews2026-02-02T16:06:46+00:00February 2nd, 2026|Endpoints News|
Spring Health acquires Alma, expanding insurance reach in virtual mental healthnews2026-02-02T15:43:15+00:00February 2nd, 2026|Endpoints News|
SanegeneBio licenses RNAi candidate to Genentech for $200M upfrontnews2026-02-02T14:35:38+00:00February 2nd, 2026|Endpoints News|
